Disclaimer: This post was sponsored by Biotheranostics, Inc. (Breast Cancer Index®), but the opinions and experiences shared are my own.
Not another minute…living with fear. The past few months have been full of uncertainty to say the least. As I watched family and friends take precautions to stay healthy and flatten the COVID-19 curve, I reflected on the fear and uncertainty so many of us face about our health and that of our loved ones.
Having a family history of breast cancer, I grew up knowing the importance of breast self-exams and screening. And as I got older, I noticed how the topic wasn’t being discussed nearly enough. I have talked about this with family members and friends who all share some connection with breast cancer. We all understand that sense of relief when a breast exam is clear, and we all have thought about how we would handle diagnosis and treatment. There’s always that “what if?” lingering in our minds. That is why I am so honored to partner with the maker of Breast Cancer Index because breast cancer patients should not have to live another minute with fear and uncertainty around their treatment plans.
Breast Cancer Index is the only commercially available, validated genomic test that predicts whether a woman with early-stage HR+ breast cancer is likely to benefit from anti-estrogen therapy beyond 5 years. 40% of women are non-compliant with their long-term breast cancer treatment, often due to the side effects of taking their anti-estrogen therapy. Breast Cancer Index provides important information, which along with other clinical information, helps breast cancer patients and their doctor make a decision about the appropriate length of anti-estrogen treatment. (Click to learn more about what to expect and intended use and limitations from the Breast Cancer Index test: https://www.breastcancerindex.com/what-to-expect)